These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 33030641)

  • 41. Performance of Breast Cancer Polygenic Risk Scores in 760 Female CHEK2 Germline Mutation Carriers.
    Borde J; Ernst C; Wappenschmidt B; Niederacher D; Weber-Lassalle K; Schmidt G; Hauke J; Quante AS; Weber-Lassalle N; Horváth J; Pohl-Rescigno E; Arnold N; Rump A; Gehrig A; Hentschel J; Faust U; Dutrannoy V; Meindl A; Kuzyakova M; Wang-Gohrke S; Weber BHF; Sutter C; Volk AE; Giannakopoulou O; Lee A; Engel C; Schmidt MK; Antoniou AC; Schmutzler RK; Kuchenbaecker K; Hahnen E
    J Natl Cancer Inst; 2021 Jul; 113(7):893-899. PubMed ID: 33372680
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Genetic testing results in Slovenian male breast cancer cohort indicate the BRCA2 7806-2A > G founder variant could be associated with higher male breast cancer risk.
    Strojnik K; Krajc M; Dragos VS; Stegel V; Novakovic S; Blatnik A
    Breast Cancer Res Treat; 2021 Aug; 188(3):811-820. PubMed ID: 33891299
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Family history and pathogenic/likely pathogenic germline variants in prostate cancer patients.
    Sabol RA; Ledet EM; Jaeger E; Hatton W; Moses M; Lankford A; Zaheria A; Barata P; Layton JL; Lewis BE; Sartor O
    Prostate; 2021 May; 81(7):427-432. PubMed ID: 33760238
    [TBL] [Abstract][Full Text] [Related]  

  • 44. A study of over 35,000 women with breast cancer tested with a 25-gene panel of hereditary cancer genes.
    Buys SS; Sandbach JF; Gammon A; Patel G; Kidd J; Brown KL; Sharma L; Saam J; Lancaster J; Daly MB
    Cancer; 2017 May; 123(10):1721-1730. PubMed ID: 28085182
    [TBL] [Abstract][Full Text] [Related]  

  • 45. [The clinical importance of a genetic analysis of moderate-risk cancer susceptibility genes in breast and other cancer patients from the Czech Republic].
    Pohlreich P; Kleibl Z; Kleiblová P; Janatová M; Soukupová J; Macháčková E; Házová J; Vašíčková P; Sťahlová Hrabincová E; Navrátilová M; Svoboda M; Foretová L
    Klin Onkol; 2012; 25 Suppl():S59-66. PubMed ID: 22920209
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Concurrent germline BRCA1, BRCA2, and CHEK2 pathogenic variants in hereditary breast cancer: a case series.
    Sukumar J; Kassem M; Agnese D; Pilarski R; Ramaswamy B; Sweet K; Sardesai S
    Breast Cancer Res Treat; 2021 Apr; 186(2):569-575. PubMed ID: 33507482
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Functional Analysis Identifies Damaging CHEK2 Missense Variants Associated with Increased Cancer Risk.
    Boonen RACM; Wiegant WW; Celosse N; Vroling B; Heijl S; Kote-Jarai Z; Mijuskovic M; Cristea S; Solleveld-Westerink N; van Wezel T; Beerenwinkel N; Eeles R; Devilee P; Vreeswijk MPG; Marra G; van Attikum H
    Cancer Res; 2022 Feb; 82(4):615-631. PubMed ID: 34903604
    [TBL] [Abstract][Full Text] [Related]  

  • 48. The Burden of Breast Cancer Predisposition Variants Across The Age Spectrum Among 10 000 Patients.
    Chavarri-Guerra Y; Hendricks CB; Brown S; Marcum C; Hander M; Segota ZE; Hake C; Sand S; Slavin TP; Hurria A; Soto-Perez-de-Celis E; Nehoray B; Blankstein KB; Blazer KR; Weitzel JN;
    J Am Geriatr Soc; 2019 May; 67(5):884-888. PubMed ID: 31012959
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Prognostic Significance of CHEK2 Mutation in Progression of Breast Cancer.
    Ansari N; Shahrabi S; Khosravi A; Shirzad R; Rezaeean H
    Lab Med; 2019 Jul; 50(3):e36-e41. PubMed ID: 31220302
    [TBL] [Abstract][Full Text] [Related]  

  • 50. [Genotyping of BRCA1, BRCA2 and CHEK2 germline mutations in Russian breast cancer patients using diagnostic biochips].
    Nasedkina TV; Gromyko OE; Emel'ianova MA; Ignatova EO; Kazubskaia TP; Portnoĭ SM; Zasedatelev AS; Liubchenko LN
    Mol Biol (Mosk); 2014; 48(2):243-50. PubMed ID: 25850293
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Trends and timing of risk-reducing mastectomy uptake in unaffected BRCA1 and BRCA2 carriers in Slovenia.
    Ložar T; Žgajnar J; Perhavec A; Blatnik A; Novaković S; Krajc M
    Eur J Surg Oncol; 2021 Aug; 47(8):1900-1906. PubMed ID: 33812767
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Breast and colorectal cancer risks among over 6,000 CHEK2 pathogenic variant carriers: A comparison of missense versus truncating variants.
    Mundt E; Mabey B; Rainville I; Ricker C; Singh N; Gardiner A; Manley S; Slavin T
    Cancer Genet; 2023 Nov; 278-279():84-90. PubMed ID: 37839337
    [TBL] [Abstract][Full Text] [Related]  

  • 53. A novel CHEK2 variant identified by next generation sequencing in an Indian family with hereditary breast cancer syndrome.
    Bhai P; Saxena R; Kulshrestha S; Verma IC
    Cancer Genet; 2019 Jun; 235-236():13-17. PubMed ID: 31296309
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Comparing breast cancer imaging characteristics of CHEK2 with BRCA1 and BRCA2 gene mutation carriers.
    Ghunaim H; Laenen A; De Keyzer F; Soens J; Keupers M; Postema S; Neven P; Van Ongeval C
    Eur J Radiol; 2022 Jan; 146():110074. PubMed ID: 34902667
    [TBL] [Abstract][Full Text] [Related]  

  • 55. The heterogeneous cancer phenotype of individuals with biallelic germline pathogenic variants in CHEK2.
    Hinić S; Cybulski C; Van der Post RS; Vos JR; Schuurs-Hoeijmakers J; Brugnoletti F; Koene S; Vreede L; van Zelst-Stams WAG; Kets CM; Haadsma M; Spruijt L; Wevers MR; Evans DG; Wimmer K; Schnaiter S; Volk AE; Möllring A; de Putter R; Soikkonen L; Kahre T; Tooming M; de Jong MM; Vaz F; Mensenkamp AR; Genuardi M; Lubinski J; Ligtenberg M; Hoogerbrugge N; de Voer RM
    Genet Med; 2024 May; 26(5):101101. PubMed ID: 38362852
    [TBL] [Abstract][Full Text] [Related]  

  • 56. [CHEK2-mutation in Dutch breast cancer families: expanding genetic testing for breast cancer].
    Adank MA; Hes FJ; van Zelst-Stams WA; van den Tol MP; Seynaeve C; Oosterwijk JC
    Ned Tijdschr Geneeskd; 2015; 159():A8910. PubMed ID: 26332814
    [TBL] [Abstract][Full Text] [Related]  

  • 57. [Frequency of CHEK2 gene mutations in patients with breast cancer from the Republic of Bashkortostan].
    Mol Biol (Mosk); 2014; 48(1):55-61. PubMed ID: 25842825
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Increased Risk for Other Cancers in Addition to Breast Cancer for CHEK2*1100delC Heterozygotes Estimated From the Copenhagen General Population Study.
    Näslund-Koch C; Nordestgaard BG; Bojesen SE
    J Clin Oncol; 2016 Apr; 34(11):1208-16. PubMed ID: 26884562
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Spectrum of mutations in BRCA1, BRCA2, CHEK2, and TP53 in families at high risk of breast cancer.
    Walsh T; Casadei S; Coats KH; Swisher E; Stray SM; Higgins J; Roach KC; Mandell J; Lee MK; Ciernikova S; Foretova L; Soucek P; King MC
    JAMA; 2006 Mar; 295(12):1379-88. PubMed ID: 16551709
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Insight into genetic susceptibility to male breast cancer by multigene panel testing: Results from a multicenter study in Italy.
    Rizzolo P; Zelli V; Silvestri V; Valentini V; Zanna I; Bianchi S; Masala G; Spinelli AM; Tibiletti MG; Russo A; Varesco L; Giannini G; Capalbo C; Calistri D; Cortesi L; Viel A; Bonanni B; Azzollini J; Manoukian S; Montagna M; Peterlongo P; Radice P; Palli D; Ottini L
    Int J Cancer; 2019 Jul; 145(2):390-400. PubMed ID: 30613976
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.